Minerva Neurosciences share price logo

Minerva Neurosciences

NASDAQ: NERV

$2.16

-0.04

(-1.82%)

as on

Minerva Neurosciences Stock Performance

as on November 18, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $2.04
    $2.29
    downward going graph

    5.56%

    Downside

    6.02%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.96
    $8.80
    downward going graph

    9.26%

    Downside

    307.41%

    Upside

    downward going graph

Minerva Neurosciences share price movements today

Previous Close
$2.20
Open
$2.22
Volume
524.0K
Market Cap
$114.1M
Day's Low - High
$2.04 - $2.29
52 Week Low - High
$1.96 - $8.80

Minerva Neurosciences Historical Returns

1 Month Return
-8.09 %
3 Month Return
-52.42 %
1 Year Return
-49.77 %
3 Year Return
-58.62 %
5 Year Return
-77.12 %

Minerva Neurosciences Stock Fundamentals & Key Indicators

Check Minerva Neurosciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$114.1M

EPS (TTM)

-26.07

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.08

Industry PE ratio

-2.92

PEG Ratio

0.00

EBITDA

-290.9M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

167.68%

Minerva Neurosciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Minerva Neurosciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neutral$114.1M-77.12%-0.080.00%0.00%
Neutral$100.6B0.07%-35.1828.00%0.00%
StrongBuy$47.2BNA65.7688.39%0.00%
StrongBuy$136.4B188.12%34.1185.53%0.00%
Buy$98.5B47.69%20.2985.77%0.39%

Stock Returns calculator for Minerva Neurosciences Stock including INR - Dollar returns

The Minerva Neurosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Minerva Neurosciences investment value today

Current value as on today

₹52,966

Returns

-₹47,034

(-47.03%)

Returns from Minerva Neurosciences Stock

-₹49,767 (-49.77%)

Dollar Impact

₹2,734 (+2.73%)

Analyst Recommendation on Minerva Neurosciences Stock

Based on 1 analysts

HOLD

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'HOLD' rating for Minerva Neurosciences. Average target price of $10.33

Minerva Neurosciences Share Price Target

Get share price movements and forecasts by analysts on Minerva Neurosciences.

What analysts predicted

79.09%UPSIDE

Target Price

$10.33

Current Price

$2.16

Analyzed by

1 Analysts

High

$7

Target

$10.33

Low

$7

Minerva Neurosciences target price $10.33, a slight upside of 79.09% compared to current price of $2.16. According to 1 analysts rating.

Indian Investors' Interest in Minerva Neurosciences Stock

Search interest for Minerva Neurosciences Stock has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-22% versus previous 30 day period

Minerva Neurosciences Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
-
-
-
Operating Income
-6
-4
-4
-3
-3
-2
-4
-16
-10
-9
EBITDA
-5
22
-4
-3
-3
-2
-283
-125
17
100
Interest Expense
2
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
-
-
-
Income Before Tax
-8
22
-4
-3
-3
-2
-283
-125
17
100
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-8
22
-4
-3
-3
-2
-283
-125
17
100
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Minerva Neurosciences Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
41
-
-
-
-
-
Gross Profit
0
0
0
41
-
-
-
-
-
Operating Income
-41
-51
-75
1
-45
-25
-23
-21
-15
EBITDA
-40
-50
-74
2
-45
-24
-21
6
-293
Interest Expense
0
0
-
-
6
7
8
4
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-40
-50
-74
1
-51
-32
-30
1
-293
Income Tax Expense
-9
1
-2
-
-1
-
-
-
-
Net Income
-31
-50
-72
1
-49
-32
-30
1
-293
Net Profit Margin
0.00%
0.00%
0.00%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Minerva Neurosciences Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-8
22
-4
-3
-3
-2
-283
-125
17
100
Operating Cash Flow
-3
-4
-5
-4
-2
-2
-4
-5
-13
-8
Investing Cash Flow
-
-
-
-
-
-
-
-45
-4
-5
Financing Cash Flow
-
-
-
-
-
0
74
1
10
9
Change in Cash
-3
-4
-5
-4
-2
-2
70
-49
-8
-4

Minerva Neurosciences Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-31
-50
-72
1
-49
-32
-30
1
-293
Operating Cash Flow
3
-41
-43
-33
-24
-24
-14
-19
-13
Investing Cash Flow
-107
69
14
24
-
0
-
-
-
Financing Cash Flow
47
-3
0
13
60
0
19
-
74
Change in Cash
-56
24
-28
3
35
-24
4
-19
60

Global Institutional Holdings in Minerva Neurosciences

Check out the Institutions with significant holdings in Minerva Neurosciences.

Funds
Holdings
BlackRock, Inc.
4.92%
Andrew J.M. Spokes
4.75%
Vanguard
3.74%
VANGUARD INDEX FUNDS
3.67%
iShares
2.53%

Minerva Neurosciences News & Key Events

  • img

    Today's Timeline - 21 October

    Tue, 06:40 PM

    -

    Minerva Neurosciences announces $200 million funding for roluperidone development, including $80 million upfront for Phase 3 trial.

Insights on Minerva Neurosciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 763.8% return, outperforming this stock by 812.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 181.6% return, outperforming this stock by 239.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, NERV stock has moved down by -14.1%

About Minerva Neurosciences

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
OrganisationMinerva Neurosciences
Headquarters1500 District Avenue, Burlington, MA, 01803, US
IndustryBiotechnology
CEORemy Luthringer

Key Management of Minerva Neurosciences

Name

Title

Mr. William B. Boni

Vice President of Investor Relations & Corporate Communications

Mr. James O'Connor

Chief Business Officer & General Counsel

Prof. Michael Davidson M.D.

Member of Scientific Advisory Board & Chief Medical Officer

Dr. Remy Luthringer Ph.D.

Executive Chairman, CEO & Member of Scientific Advisory Board

Mr. Frederick W. Ahlholm CPA

Senior VP, CFO & Secretary

Mr. Joseph Reilly

Senior VP & COO

Mr. Anthony Aliquo

Chief Accounting Officer & Principal Accounting Officer

FAQs

What is Minerva Neurosciences share price today?

Minerva Neurosciences share price today is $2.16 as on at the close of the market. Minerva Neurosciences share today touched a day high of $2.29 and a low of $2.04.

What is the 52 week high and 52 week low for Minerva Neurosciences share?

Minerva Neurosciences share touched a 52 week high of $8.80 on and a 52 week low of $1.96 on . Minerva Neurosciences stock price today i.e. is closed at $2.16,which is 75.45% down from its 52 week high and 10.20% up from its 52 week low.

What is Minerva Neurosciences's market capitalisation today?

Minerva Neurosciences market capitalisation is $0.00T as on .

How to invest in Minerva Neurosciences Stock (NERV) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Minerva Neurosciences on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Minerva Neurosciences Stock (NERV) from India?

Indian investors can start investing in Minerva Neurosciences (NERV) shares with as little as ₹93.459999084473 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹934.60 in Minerva Neurosciences stock (as per the Rupee-Dollar exchange rate as on ). Based on Minerva Neurosciences share’s latest price of $2.16 as on November 18, 2026 at 8:45 am IST, you will get 4.6296 shares of Minerva Neurosciences. Learn more about fractional shares .

What are the returns that Minerva Neurosciences has given to Indian investors in the last 5 years?

Minerva Neurosciences stock has given -77.12% share price returns and 26.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?